180081-10-1 Usage
General Description
Tert-butyl (2-(4-aminophenyl)-2-methylpropyl)carbamate is a chemical compound that is also known as tadalafil. It is commonly used in the treatment of erectile dysfunction and pulmonary arterial hypertension. Tadalafil works by inhibiting the action of phosphodiesterase type 5, which helps to relax the smooth muscles in the blood vessels and increase blood flow to certain areas of the body. It is a prescription medication and should be taken under the guidance of a healthcare professional. Side effects may include headaches, muscle pain, indigestion, and flushing. Tadalafil should not be used in combination with nitrates as it can cause a dangerous drop in blood pressure.
Check Digit Verification of cas no
The CAS Registry Mumber 180081-10-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,0,8 and 1 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 180081-10:
(8*1)+(7*8)+(6*0)+(5*0)+(4*8)+(3*1)+(2*1)+(1*0)=101
101 % 10 = 1
So 180081-10-1 is a valid CAS Registry Number.
InChI:InChI=1/C15H24N2O2/c1-14(2,3)19-13(18)17-10-15(4,5)11-6-8-12(16)9-7-11/h6-9H,10,16H2,1-5H3,(H,17,18)
180081-10-1Relevant articles and documents
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
